The once-weekly autoinjector is cleared for type 2 diabetes, overweight and obesity. Lilly never officially sold Mounjaro in Russia, and its rights there ended in November 2024.
Recap by typeshit. Full story at Новости GxP.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Bodybuilder Sam Sulek gives his take on peptides in a short clip from Chris Williamson's show. His views are his own, not medical guidance.
Superpower frames apitegromab's FDA approval as a big step and ties it to concern that GLP-1 users can lose a lot of muscle along with fat.
Medscape examines how people on GLP-1 medications can be judged both for their weight and for using a drug to treat it.
Moneycontrol says the Indian drugmaker is focusing on specialised production of peptides and antibody-drug conjugates rather than crowded weight loss drugs.
Loading…